United States securities and exchange commission logo





                             August 2, 2021

       Tillman U. Gerngross, Ph.D.
       Chief Executive Officer
       Adagio Therapeutics, Inc.
       303 Wyman Street, Suite 300
       Waltham, MA 02451

                                                        Re: Adagio
Therapeutics, Inc.
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed August 2,
2021
                                                            File No. 333-257975

       Dear Dr. Gerngross:

            We have reviewed your amended registration statement and have the
following
       comment.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.

       Amendment No. 1 to Registration Statement on Form S-1 filed August 2,
2021

       Business
       License Agreement with Biocon Biologics Limited, page 145

   1.                                                   Please expand your
disclosure regarding the license agreement with Biocon to describe
                                                        the material terms of
the agreement, including payment terms and termination provisions.
                                                        Please also file the
agreement as an exhibit to the registration statement, or advise. See
                                                        Item 601(b)(10) of
Regulation S-K.
 Tillman U. Gerngross, Ph.D.
Adagio Therapeutics, Inc.
August 2, 2021
Page 2



       You may contact Tara Harkins at 202-551-3639 or Al Pavot at 202-551-3738
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Abby Adams at 202-551-6902 or Irene Paik at 202-551-6553 with any other
questions.



                                                         Sincerely,
FirstName LastNameTillman U. Gerngross, Ph.D.
                                                         Division of
Corporation Finance
Comapany NameAdagio Therapeutics, Inc.
                                                         Office of Life
Sciences
August 2, 2021 Page 2
cc:       Divakar Gupta, Esq.
FirstName LastName